Voyageur Pharmaceuticals is advancing its strategy to vertically integrate the barium and iodine contrast media supply chain. The company is currently completing bankable feasibility studies for its Frances Creek barium project and its iodine production initiatives.
Voyageur Pharmaceuticals has confirmed that its Frances Creek barite achieves pharmaceutical-grade purity, with average BaSO4 levels of 98.8%, exceeding USP requirements. The company is progressing toward Health Canada human trials and has secured support through the Alberta Innovates program.
Voyageur Pharmaceuticals has commenced its first commercial shipments of Health Canada-approved barium contrast products to Canadian clinics. The company highlighted its Frances Creek Project in British Columbia, which contains a 121,000-tonne indicated and inferred barium sulfate resource with significant cost advantages over synthetic imports.
